Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Neurobiol. 2012 Aug;46(1):136-50. doi: 10.1007/s12035-012-8271-z. Epub 2012 May 3.

Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Author information

1
Department of Pharmacology, Biocenter, Campus Riedberg, Goethe-University, Biocentre Geb. N260, R.1.09, Max-von-Laue Str. 9, 60438 Frankfurt, Germany. g.p.eckert@em.uni-frankfurt.de

Abstract

Increasing evidences suggest that mitochondrial dysfunction plays an important role in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD). Alterations of mitochondrial efficiency and function are mainly related to alterations in mitochondrial content, amount of respiratory enzymes, or changes in enzyme activities leading to oxidative stress, mitochondrial permeability transition pore opening, and enhanced apoptosis. More recently, structural changes of the network are related to bioenergetic function, and its consequences are a matter of intensive research. Several mitochondria-targeting compounds with potential efficacy in AD including dimebon, methylene blue, piracetam, simvastatin, Ginkgo biloba, curcumin, and omega-3 polyunsaturated fatty acids have been identified. The majority of preclinical data indicate beneficial effects, whereas most controlled clinical trials did not meet the expectations. Since mitochondrial dysfunction represents an early event in disease progression, one reason for the disappointing clinical results could be that pharmacological interventions might came too late. Thus, more studies are needed that focus on therapeutic strategies starting before severe disease progress.

PMID:
22552779
DOI:
10.1007/s12035-012-8271-z
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center